This is a working overview of intranasal delivery, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-18. Anything still debated is marked as such rather than presented as settled.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
| Property | Value | Notes |
|---|---|---|
| Typical purity report | 95% or higher by HPLC | Area percentage at 214 nm |
| Identity confirmation | Mass spectrometry | Electrospray or MALDI |
| Powder storage | -20 C, desiccated | Protect from light |
| Solution storage | 2-8 C short term | Freeze aliquots for longer |
| Quality document | Certificate of analysis | States method and value |
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
In zero field NMR all magnetic fields are shielded such that magnetic fields below 1 nT (nanotesla) are achieved and the nuclear precession frequencies of all nuclei are close to zero and indistinguishable. Under those circumstances the observed spectra are no-longer dictated by chemical shifts but primarily by J-coupling interactions which are independent of the external magnetic field. Since inductive detection schemes are not sensitive at very low frequencies, on the order of the J-couplings (typically between 0 and 1000 Hz), alternative detection schemes are used. Specifically, sensitive magnetometers turn out to be good detectors for zero field NMR. A zero magnetic field environment does not provide any polarization hence it is the combination of zero field NMR with hyperpolarization schemes that makes zero field NMR desirable.
== Facility == FMC Rochester is one of six medical referral centers within the Federal Bureau of Prisons. Health Services staff at FMC include physicians, a dentist, dental assistants, nurse practitioners, physician assistants, nurses, pharmacists, pharmacy technicians, a radiological technician, physical therapists, laboratory technologists and a respiratory therapist. Mental Health Services through the Psychiatry and Psychology Departments are available to all inmates. These include educational groups, therapy groups, individual therapy, intensive diagnosis/assessment, and inpatient treatment. In addition, outpatient substance abuse treatment services are available. In 2009, Philip Fornaci, the director of the DC Prisoners' Project, stated that Rochester, along with FMC Butner and FMC Carswell, "are clearly the "gold standard" in terms of what BOP facilities can achieve in providing medical care" and that they had provided "excellent medical care, sometimes for extremely complex medical needs."
==== Eliminated in primary ==== Jay Fondren, nonprofit official Stephen Long Nick Tran, businessman (previously ran in the 2nd district) Deddrick Wilmer, mortage broker (previously ran in the 9th district)
Sources: en.wikipedia.org
=== Tobacco === Polonium-210 in tobacco contributes to many of the cases of lung cancer worldwide. Most of this polonium is derived from lead-210 deposited on tobacco leaves from the atmosphere; the lead-210 is a product of radon-222 gas, much of which appears to originate from the decay of radium-226 from fertilizers applied to the tobacco soils. The presence of polonium in tobacco smoke has been known since the early 1960s. Some of the world's biggest tobacco firms researched ways to remove the substance—to no avail—over a 40-year period. The results were never published.
== Sequence == More than 100 AKH sequences are known. The typical makeup of hormones in this family includes a length between 8 and 10 amino acids, blocked N (pyroglutamic acid) and C (amidation) termini, with hydrophic residues at position 2, asparagine or threonine at position 3, phenylalanine or tyrosine at position 4, and serine or threonine at position 5. AKH sequence characteristics also include tryptophan at position 8 and in about two-thirds of the known AKHs, proline at position 6. AKHs can be modified (C-mannosylated tryptophan, proline hydroxylation, threonine phosphorylation, possible proline isomerisation, threonine O-sulfonation). Mass spectrometry is increasingly used for de novo sequencing of these hormones. Sequence prediction from genomic and transcriptomic data assist in hormone identification . AKH sequences differ slightly in insect families (Scarabaeoidea, Cucujiformia, Lepidoptera, Diptera, Hemiptera, Polyphaga).
== Release == The film premiered at the 62nd Cannes Film Festival on 18 May 2009, and went on to screen at festivals such as the Toronto International Film Festival and the Maryland Film Festival. It was released in Greece on 11 November 2009 by Feelgood Entertainment. Verve Pictures acquired distribution rights for the United Kingdom and released it on 23 April 2010. Kino International released it in the United States on 25 June 2010.
Sources: en.wikipedia.org
=== Infectious disease === The breath of patients infected with Aspergillus fumigatus, a fungus responsible for invasive aspergillosis, showed the presence of 2-pentylfuran, a compound not ordinarily produced in mammalian metabolism. VOC profiles may be confounded by intakes of peanuts, soy milk, and more, which also display 2-pentylfuran. Patients with cystic fibrosis (CF) had a significantly higher level of ethane than individuals without CF, correlating with increased carbon monoxide levels and obstructed airways. For CF caused by P. aeruginosa infection, hydrogen cyanide, 2-aminoacetophenone, and methyl thiocyanate were identified as potential breath biomarkers.
== Risk factors affecting food distribution and examples of failed policy == Prominent risk factors that can affect the food distribution within a society include war, economic failure, political instability, and weather conditions. Each of these factors affects individual groups of people differently, but all share the common attribute of being detrimental to local food distribution and food systems. Two prominent examples of risk factors' negative effect on a society's food distribution system are the situation in Japan during World War II and Africa during the late 1970s and early 1980s.
That same year, the American Food and Drug Administration issued a safety alert advising medical professionals to dispose of all Lyodura that they could not confirm was from a different batch than the contaminated one, then an import alert stating that Lyodura was believed to carry Creutzfeldt–Jakob disease and shipments of it should be stopped by US customs agents as an "adulterated drug". The Australian Therapeutic Goods Administration also revoked its approval for use in 1987. The manufacturer did not keep records that allowed contaminated product to be traced back to a specific donor. According to an article published in 1991, "unsubstantiated reports suggested that donor screening was not rigidly adhered to." The cost was around $300 Canadian Dollars for a piece the size of a postage stamp. Lyodura was removed from sale in 1996. The World Health Organization recommended in 1997 that the medical field move away from cadaver-sourced dura mater grafts due to the risk of transmitting Creutzfeldt–Jakob disease highlighted by Lyodura-related cases. Dural grafts are now made from bovine tissue, various synthetic materials, or part of the patient's own body. The product's largest consumer was Japan. By 2017, 154 patients in Japan had been diagnosed with Creutzfeldt–Jakob disease after receiving dural grafts. Every patient where the brand of graft could be identified from medical records had received a Lyodura graft. Patients continued to develop symptoms up to thirty years after their surgery.
=== Marine alkaloids === Marine alkaloids are extracted from marine organisms living in oceans, including animals, plants, certain marine bacteria and marine fungi. They are characterized in their chemical structure by halogens, which are atypical of higher organisms and terrestrial plants. An example is tetrodotoxin, a non-protein neurotoxin about 10,000 times more toxic than cyanide. It is mainly produced by the pufferfish and blue-ringed octopus, but occurs in 140 animal species worldwide. Although numerous theories address the origin of tetrodotoxin, the involvement of endogenous symbiotic bacteria producing toxins is prevalent.
Sources: en.wikipedia.org
Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.
Dry powder is kept frozen, desiccated, and shielded from light. Dissolved material is aliquoted and frozen to limit freeze-thaw cycles. Short-term refrigerated storage is common for working solutions.
Russia registers it as a prescription nasal product. Most other markets classify it as a research chemical with no approved medical use. Oversight of purity and labeling is consequently minimal in those markets.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.